What is Dendreon?
Founded in 1992 and headquartered in Seal Beach, California, Dendreon operates within the biotechnology sector, focusing on the development and manufacturing of immune-therapeutics designed for cancer treatments. The company's specialization in this area positions it within a critical segment of medical innovation, aiming to address unmet needs in oncology.
How much funding has Dendreon raised?
Dendreon has raised a total of $50M across 2 funding rounds:
Stock Offering
$45M
Debt
$5M
Stock Issuance/Offering (2000): $45M, investors not publicly disclosed
Debt (2020): $5M led by PPP
Key Investors in Dendreon
PPP
Public-Private Partnership
What's next for Dendreon?
The recent major strategic investment signifies a pivotal moment for Dendreon, likely enabling the company to accelerate its research and development pipelines, expand manufacturing capabilities, or pursue further clinical trials. This infusion of capital, within the context of a significant enterprise-level funding, suggests a strategic push towards scaling operations and solidifying its market presence in the advanced therapeutics domain.
See full Dendreon company page